title: Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy.
abstract: The causes of multiple myeloma (MM) remain obscure and there are few known risk factors; however, natural killer T (NKT) cell abnormalities have been reported in patients with MM, and therapeutic targeting of NKT cells is promoted as a potential treatment. We characterized NKT cell defects in treated and untreated patients with MM and determined the impact of lenalidomide therapy on the NKT cell pool. Lenalidomide is an immunomodulatory drug with co-stimulatory effects on NKT cells in vitro and is an approved treatment for MM, although its mode of action in that context is not well defined. We find that patients with relapsed/progressive MM had a marked deficiency in NKT cell numbers. In contrast, newly diagnosed patients had relatively normal NKT cell frequency and function prior to treatment, although a specific NKT cell deficiency emerged after high-dose melphalan and autologous stem cell transplantation (ASCT) regimen. This also impacted NK cells and conventional T cells, but the recovery of NKT cells was considerably delayed, resulting in a prolonged, treatment-induced NKT cell deficit. Longitudinal analysis of individual patients revealed that lenalidomide therapy had no in-vivo impact on NKT cell numbers or cytokine production, either as induction therapy, or as maintenance therapy following ASCT, indicating that its clinical benefits in this setting are independent of NKT cell modulation.
authors.affiliation: Department of Microbiology and Immunology, University of Melbourne, Parkville, Vic., Australia.
authors.forename: A C
authors.initials: AC
authors.lastname: Chan
authors.forename: P
authors.initials: P
authors.lastname: Neeson
authors.forename: E
authors.initials: E
authors.lastname: Leeansyah
authors.forename: K
authors.initials: K
authors.lastname: Tainton
authors.forename: H
authors.initials: H
authors.lastname: Quach
authors.forename: H M
authors.initials: HM
authors.lastname: Prince
authors.forename: S J
authors.initials: SJ
authors.lastname: Harrison
authors.forename: D I
authors.initials: DI
authors.lastname: Godfrey
authors.forename: D
authors.initials: D
authors.lastname: Ritchie
authors.forename: S P
authors.initials: SP
authors.lastname: Berzins
mesh_terms: D016207:Cytokines / Q000097:blood / Q000276:immunology; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D000077269:Lenalidomide; D018655:Lymphocyte Count; D008297:Male; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D055611:Natural Killer T-Cells / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D016207:Cytokines; D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide
keywords: NKT cells; lenalidomide; multiple myeloma
references.citation: Nat Rev Immunol. 2011 Feb;11(2):131-42
references.pmid: 21267014
references.citation: J Exp Med. 2005 May 2;201(9):1503-17
references.pmid: 15867097
references.citation: Curr Opin Immunol. 2010 Dec;22(6):807-13
references.pmid: 21115332
references.citation: Curr Opin Oncol. 2012 Jan;24 Suppl 2:S3-11
references.pmid: 22245806
references.citation: Adv Cancer Res. 2008;101:277-348
references.pmid: 19055947
references.citation: J Clin Invest. 2004 Nov;114(10):1379-88
references.pmid: 15545985
references.citation: J Invest Dermatol. 2009 Jul;129(7):1628-42
references.pmid: 19262602
references.citation: Blood. 2001 Jul 1;98(1):210-6
references.pmid: 11418482
references.citation: Recent Pat Inflamm Allergy Drug Discov. 2010 Jun;4(2):144-8
references.pmid: 20307255
references.citation: J Exp Med. 2003 Jun 16;197(12):1667-76
references.pmid: 12796469
references.citation: Tumour Biol. 2013 Jun;34(3):1349-60
references.pmid: 23504588
references.citation: Clin Cancer Res. 2008 Nov 1;14(21):6955-62
references.pmid: 18980990
references.citation: Blood. 2006 Jul 15;108(2):618-21
references.pmid: 16569772
references.citation: Leukemia. 2010 Jan;24(1):22-32
references.pmid: 19907437
references.citation: Cancer Immunol Immunother. 2008 Dec;57(12):1849-59
references.pmid: 18392823
references.citation: Blood. 2013 Jan 17;121(3):423-30
references.pmid: 23100308
references.citation: Blood. 2011 Feb 3;117(5):1605-13
references.pmid: 20978269
references.citation: Leukemia. 2010 Mar;24(3):592-600
references.pmid: 20072154
references.citation: Blood. 2010 Oct 28;116(17):3227-37
references.pmid: 20651070
references.citation: J Exp Med. 2005 Nov 7;202(9):1279-88
references.pmid: 16275765
references.citation: J Exp Med. 2002 Mar 4;195(5):625-36
references.pmid: 11877485
references.citation: PLoS One. 2013 May 31;8(5):e65075
references.pmid: 23741460
references.citation: J Exp Med. 2002 Mar 4;195(5):637-41
references.pmid: 11877486
references.citation: Blood. 2008 Aug 15;112(4):1308-16
references.pmid: 18535199
references.citation: Curr Mol Med. 2009 Feb;9(1):4-14
references.pmid: 19199937
references.citation: Annu Rev Immunol. 2007;25:297-336
references.pmid: 17150027
references.citation: Nat Rev Immunol. 2009 Jan;9(1):28-38
references.pmid: 19079136
references.citation: Nat Rev Immunol. 2012 Mar 22;12(4):239-52
references.pmid: 22437937
references.citation: Clin Immunol. 2011 Aug;140(2):160-6
references.pmid: 21233022
references.citation: Blood. 2009 Mar 12;113(11):2498-507
references.pmid: 19056691
references.citation: Drugs. 2007;67(13):1869-81
references.pmid: 17722955
references.citation: Trends Immunol. 2007 Nov;28(11):491-6
references.pmid: 17964217
references.citation: Clin Immunol. 2001 Aug;100(2):144-8
references.pmid: 11465942
references.citation: Blood. 2013 Jan 17;121(3):418-20
references.pmid: 23329692
references.citation: Clin Exp Immunol. 2013 Apr;172(1):129-37
references.pmid: 23480193
references.citation: Curr Top Microbiol Immunol. 2007;314:293-323
references.pmid: 17593666
references.citation: Nat Rev Immunol. 2004 Mar;4(3):231-7
references.pmid: 15039760
references.citation: Ann N Y Acad Sci. 2009 Sep;1174:61-7
references.pmid: 19769737
references.citation: Best Pract Res Clin Haematol. 2007 Dec;20(4):665-80
references.pmid: 18070712